Pay in 4 interest-free payments of $5.81 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The oral small-molecule inhibitor INCB001158 (CB-1158), targeting this axis, has entered first-inhuman phase I studies and has been explored in combination with PD-1 inhibitors, suggesting that relieving substrate depletion-driven immunosuppression is clinically feasible from a safety and pharmacodynamic perspective, although its therapeutic efficacy remains to be fully established (116)
Why Choose Peptides
BPC-157 has a short elimination half-life under 30 minutes following injection, meaning the peptide rapidly enters circulation and distributes to tissues
Ready to glow
US$ 28.23
US$ 24.39
US$ 22.47
US$ 29.50
US$ 20.72
US$ 22.14
US$ 26.69
US$ 25.56
US$ 29.43
US$ 27.23
